Future Science - Athens authentication
Future Science Group is pleased to announce that it is now fully compliant with Athens authentication. This arrangement guarantees that customers have maximum flexibility when accessing journal content via their robust online platforms www.futuremedicine.com and www.future-drugs.com.
Athens, developed by Eduserv, is the British standard to access Web-based subscription services for academic centres and hospitals. The system enables these institutions to efficiently manage access rights to multiple online resources.
Future Science Groups support for the Athens Access Management System means that users from academic centres and hospitals throughout the UK can now benefit from access to Future Science Group content using Athens Single Sign On (SSO) technology. This technology enables the use of the same login credentials to access multiple information resources, so that users can link seamlessly to other Athens SSO-protected information. By offering support for all the major authentication standards, Athens allows institutions the opportunity to evolve their authentication procedures at their own pace.
Dr David Hughes, Publisher for the Future Science Group, commented; ‘Developing a robust on-line platform for the dissemination of published scholarly work is a constantly evolving task. By enabling Athens authentication on our Future Drugs and Future Medicine websites, we recognize the importance of developing our on-line presence to reflect the needs of the academic & hospital sectors. As these needs evolve further we will work to ensure that our on-line presence is at the forefront of these developments. To this end, we are currently working to enable Shibboleth authentication, and plan to role this feature out to end users in 2007.’
The Future Science Group, incorporating Future Drugs and Future Medicine, provides a critical mass of evaluated commentary in clinical medicine – 35 titles will deliver more than 3,000 reviews in 2007. Each title delivers high-quality, evaluated and structured content from international opinion leaders, with industry leading publication times.